JPS6216929B2 - - Google Patents
Info
- Publication number
- JPS6216929B2 JPS6216929B2 JP60185230A JP18523085A JPS6216929B2 JP S6216929 B2 JPS6216929 B2 JP S6216929B2 JP 60185230 A JP60185230 A JP 60185230A JP 18523085 A JP18523085 A JP 18523085A JP S6216929 B2 JPS6216929 B2 JP S6216929B2
- Authority
- JP
- Japan
- Prior art keywords
- prostaglandin
- pge
- solution
- freeze
- stable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 claims description 20
- 239000001913 cellulose Substances 0.000 claims description 6
- 229920002678 cellulose Polymers 0.000 claims description 6
- 150000001875 compounds Chemical class 0.000 claims description 6
- 229920000642 polymer Polymers 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 5
- 238000004108 freeze drying Methods 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- 239000000243 solution Substances 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 239000007864 aqueous solution Substances 0.000 description 5
- 239000000654 additive Substances 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 239000003960 organic solvent Substances 0.000 description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 229960002986 dinoprostone Drugs 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 229910001873 dinitrogen Inorganic materials 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- IMPVDANDCDGWFM-SLESNMHTSA-N (z)-7-[(1r,2r,3r)-3-hydroxy-2-[(e,3s)-3-hydroxy-4-methyloct-1-enyl]-5-oxocyclopentyl]hept-5-enoic acid Chemical compound CCCCC(C)[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O IMPVDANDCDGWFM-SLESNMHTSA-N 0.000 description 1
- KEJJEEMSWMJCHB-BDKFZLQASA-N (z)-7-[(1r,2r,3r)-3-hydroxy-2-[(e,3s,4s)-3-hydroxy-8-methoxy-4-methyloct-1-enyl]-5-oxocyclopentyl]hept-5-enoic acid Chemical compound COCCCC[C@H](C)[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O KEJJEEMSWMJCHB-BDKFZLQASA-N 0.000 description 1
- OBUOTEZRDMDNCG-ULXDGKDISA-N CCCCC[C@](C)(O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(=O)OC Chemical compound CCCCC[C@](C)(O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(=O)OC OBUOTEZRDMDNCG-ULXDGKDISA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 206010061459 Gastrointestinal ulcer Diseases 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 230000003182 bronchodilatating effect Effects 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- GMVPRGQOIOIIMI-DWKJAMRDSA-N prostaglandin E1 Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O GMVPRGQOIOIIMI-DWKJAMRDSA-N 0.000 description 1
- CBOMORHDRONZRN-QLOYDKTKSA-N prostaglandin E3 Chemical compound CC\C=C/C[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O CBOMORHDRONZRN-QLOYDKTKSA-N 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP18523085A JPS61171421A (ja) | 1985-08-23 | 1985-08-23 | 安定なプロスタグランジンｅ類製剤の製造方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP18523085A JPS61171421A (ja) | 1985-08-23 | 1985-08-23 | 安定なプロスタグランジンｅ類製剤の製造方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS61171421A JPS61171421A (ja) | 1986-08-02 |
| JPS6216929B2 true JPS6216929B2 (sv) | 1987-04-15 |
Family
ID=16167151
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP18523085A Granted JPS61171421A (ja) | 1985-08-23 | 1985-08-23 | 安定なプロスタグランジンｅ類製剤の製造方法 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS61171421A (sv) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7772220B2 (en) | 2004-10-15 | 2010-08-10 | Seo Hong Yoo | Methods and compositions for reducing toxicity of a pharmaceutical compound |
| JP2005272458A (ja) * | 2004-02-27 | 2005-10-06 | Ono Pharmaceut Co Ltd | 経口投与用医薬組成物 |
| JP2005314413A (ja) * | 2004-04-02 | 2005-11-10 | Ono Pharmaceut Co Ltd | 経口投与用医薬組成物 |
| WO2006026555A2 (en) | 2004-08-30 | 2006-03-09 | Seo Hong Yoo | Neuroprotective effect of solubilized udca in focal ischemic model |
| CA2584184A1 (en) | 2004-10-15 | 2006-04-27 | Seo Hong Yoo | Methods and compositions for reducing toxicity of a pharmaceutical compound |
| CA2588168A1 (en) * | 2004-11-24 | 2006-06-01 | Seo Hong Yoo | Dried forms of aqueous solubilized bile acid dosage formulation: preparation and uses thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5976017A (ja) * | 1983-01-20 | 1984-04-28 | Yamanouchi Pharmaceut Co Ltd | 安定なプロスタグランジンｅ類製剤の製法 |
-
1985
- 1985-08-23 JP JP18523085A patent/JPS61171421A/ja active Granted
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5976017A (ja) * | 1983-01-20 | 1984-04-28 | Yamanouchi Pharmaceut Co Ltd | 安定なプロスタグランジンｅ類製剤の製法 |
Also Published As
| Publication number | Publication date |
|---|---|
| JPS61171421A (ja) | 1986-08-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IE52536B1 (en) | Carbonate diester solutions of pge-type compounds | |
| JP2003535893A5 (sv) | ||
| CA1056729A (en) | Injectable amoxycillin composition | |
| KR100195348B1 (ko) | 안정한 프로스타글란딘 e1-함유 주사제 조성물 | |
| US4990530A (en) | Indomethacin injections and their production method | |
| JP2526059B2 (ja) | 抗潰瘍剤 | |
| JP6165986B2 (ja) | ボルテゾミブを含む医薬組成物 | |
| JPS6216929B2 (sv) | ||
| KR890000907B1 (ko) | 안정한 현탁액 제조용 고체 약물 제형의 제조방법 | |
| NO328957B1 (no) | Farmasoytisk middel omfattende et benzamid-derivat som aktiv forbindelse | |
| JPH0136445B2 (sv) | ||
| JPS6245524A (ja) | ナトリウムフエニトイン水性製剤 | |
| JPS60149530A (ja) | 水性製剤 | |
| JP2001163776A (ja) | 安定化された液剤 | |
| JPH07157431A (ja) | 安定なプロスタグランジンｅ製剤 | |
| JPS6146454B2 (sv) | ||
| EP0055593B1 (en) | Compositions comprising e-prostaglandins | |
| JP4475405B2 (ja) | 医薬組成物 | |
| KR920006911B1 (ko) | 안정한 피록시캄 주사액 조성물 및 그의 제조방법 | |
| US6784315B2 (en) | Stilbene derivative crystal and method for producing the same | |
| JPH0219804B2 (sv) | ||
| JP2019085338A (ja) | ボルテゾミブを含有する凍結乾燥医薬組成物 | |
| KR900002745B1 (ko) | 안정 주사용 진토제 조성물의 제조방법 | |
| JPS63267727A (ja) | Ｓ−ラクトイルグルタチオンおよび／またはその塩を有効成分とする医薬 | |
| RU2545902C1 (ru) | Фармацевтическая композиция в виде лиофилизата с комплексообразующим агентом для приготовления раствора для парентерального применения и способ ее получения |